Abstracts tagged "skin"

Abstract Number: 1268 • ACR Convergence 2024
Neutrophil Lymphocyte Ratio as a Novel Marker of Skin Disease Activity in Older Children with Juvenile Dermatomyositis
Shreya Swaminathan¹, Nidhi Naik², Susan Shenoi³, Sarah Vandenbergen⁴, Jessica Turnier⁵, Zilan Zheng⁶, Jessica Neely⁶, James Andrews⁷ and Christian Lood⁸, ¹University of Washington, Seattle, ²Seattle children's hospital, Bothell, WA, ³Seattle Children's Hospital and Research Center, Mercer Island, WA, WA, ⁴University of Michigan, Ann Arbor, MI, ⁵University of Michigan, Saline, MI, ⁶UCSF, San Francisco, CA, ⁷University of Alabama at Birmingham, Birmingham, AL, ⁸University of Washington, Seattle, WA
Background/Purpose: Exaggerated neutrophil activation can lead to inflammation and organ damage in rheumatic diseases, including dermatomyositis (DM). In both juvenile (JDM) and adult DM, markers…
Abstract Number: 1831 • ACR Convergence 2024
Role of Long Non-Coding RNA H19 in Mediating Skin Fibrosis in Systemic Sclerosis
Begoña Caballero-Ruiz¹, Christopher Wasson², Rebecca Ross³ and Francesco Del Galdo², ¹Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ²University of Leeds, Leeds, United Kingdom, ³Medicine and Health, University of Leeds, Leeds, United Kingdom
Background/Purpose: Systemic Sclerosis (SSc) is an immune driven condition leading to skin fibrosis, as well as internal organs. Dermal fibroblasts are the key cellular elements…
Abstract Number: 2678 • ACR Convergence 2024
History of Cutaneous Lupus Promotes Blood and Skin Interferon Signatures in SLE Patients
Svenja Henning¹, Lam Tsoi², Craig Dobry², Celine Berthier², Benjamin Klein², Amy Hurst², Rachael Wasikowski³, Johann Gudjonsson² and J. Michelle Kahlenberg², ¹University of Groningen, Groningen, Netherlands, ²University of Michigan, Ann Arbor, MI, ³Michigan, Dept. of Dermatology, Ann Arbor, MI
Background/Purpose: Cutaneous lupus (CLE) can present in isolation or as one of the most common manifestations of systemic lupus erythematosus (SLE). Interferon (IFN) stimulated genes…
Abstract Number: 0290 • ACR Convergence 2024
Deucravacitinib Long-term Efficacy Through 4 Years in Week 16 Placebo Crossover Patients in the Phase 3 POETYK PSO-1, PSO-2, and LTE Program
Mark Lebwohl¹, Richard Warren², Shinichi Imafuku³, Jerry Bagel⁴, April W. Armstrong⁵, Thierry Passeron⁶, Subhashis Banerjee⁷, Renata M. Kisa⁸, Matthew J. Colombo⁷, Thomas Scharnitz⁸, Kim Hoyt⁸, Diamant Thaçi⁹ and Andrew Blauvelt¹⁰, ¹Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY, ²Dermatology Centre, Northern Care Alliance NHS Foundation Trust and NIHR Manchester Biomedical Research Centre, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, United Kingdom, ³Fukuoka University Hospital Faculty of Medicine, Fukuoka, Japan, ⁴Psoriasis Treatment Center of New Jersey, East Windsor, ⁵University of California Los Angeles, Los Angeles, ⁶Université Côte d’Azur, University Hospital of Nice, Nice, France, ⁷Bristol Myers Squibb, Princeton, NJ, ⁸Bristol Myers Squibb, Princeton, ⁹Institute and Comprehensive Center for Inflammation Medicine, University of Lübeck, Lübeck, Schleswig-Holstein, Germany, ¹⁰Oregon Medical Research Center, Portland, OR
Background/Purpose: Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, is approved in the US, EU, and other countries for treatment of adults with moderate…
Abstract Number: 1551 • ACR Convergence 2024
Efficacy of Belimumab on Different Phenotypes of Joint and Skin Manifestations of Systemic Lupus Erythematosus: Preliminary Data from a Multicenter, Nationwide, Cohort of Patients: The BElimumab in Real Life Setting Study-New Joint and Skin (BeRLISS-NeJS)
Luca Iaccarino¹, Marisol Bracalenti², Alberto Cauli³, Lorenzo Cavagna⁴, Rossella De Angelis⁵, Roberto Depascale², Giacomo Emmi⁶, Roberto Gerli⁷, Marcello Govoni⁸, Alberto Lo Gullo⁹, Simone Negrini¹⁰, Luca Quartuccio¹¹, Maurizio Rossini¹², Carlo Salvarani¹³, Paola Tomietto¹⁴, Angelo Vacca¹⁵, Margherita Zen¹⁶ and doria Andrea², ¹University of Padua, PADOVA, Italy, ²University of Padova, Padova, Italy, ³University of Cagliari, Cagliari, Italy, ⁴University of Pavia and Fondazione IRCCS Policlinico San Matteo Hospital of Pavia, Pavia, Pavia, Italy, ⁵Università Politecnica delle Marche, Ancona, Italy, ⁶University of Trieste, Trieste, Italy, ⁷University of Perugia, Perugia, Italy, ⁸Rheumatology Unit, Department of Medical Sciences, University of Ferrara and Azienda Ospedaliero-Universitaria S.Anna, Ferrara, Italy, Ferrara, Italy, ⁹Rheumatology Unit, Papardo Hospital, Messina, Italy, ¹⁰University of Genova, Genova, Italy, ¹¹Division of Rheumatology, Department of Medicine (DMED), University of Udine, Udine, Italy, Udine, Italy, ¹²Rheumatology Unit, University of Verona, Verona, Italy, ¹³Azienda USL-IRCCS di Reggio Emilia and University of Modena and Reggio Emilia, Reggio Emilia, Italy, Reggio Emilia, Italy, ¹⁴Azienda Sanitaria Universitaria Giuliano Isontina, trieste, Italy, ¹⁵University of Bari, Bari, Italy, ¹⁶University of Padova, Padova, Padua, Italy
Background/Purpose: To evaluate the efficacy of belimumab on different skin and joint manifestations of the disease in a multicenter, nationwide, cohort (BeRLISS-NeJS) of patients with…
Abstract Number: 1834 • ACR Convergence 2024
Altered Mechanotransduction via Myosin II Contributes to Collagen and IL-6 Production in Systemic Sclerosis Skin
Barbara Russo¹, Shutova Maria², Fanny Noulet², Geroge-Radu Romanescu³, Nicolo brembilla² and Wolf-Henning Boehncke², ¹Hopitaux Universitaire de Geneva, Geneva, Geneve, Switzerland, ²Hôpitaux Universitaires des Genève, Geneva, Geneve, Switzerland, ³University of Geneva, Geneva, Geneve, Switzerland
Background/Purpose: Scleroderma (SSc), an autoimmune disease, features progressive fibrosis, leading to significant morbidity and mortality. Current therapies manage symptoms but lack efficacy in directly targeting…
Abstract Number: 0293 • ACR Convergence 2024
Assessment of Skin Cancer Risk in Autoimmune Diseases: A Multivariate Analysis Using a National Inpatient Database
Sami Rabah and Xiangyi Kang, Lincoln Medical Center, New York, NY
Background/Purpose: Autoimmune diseases are known to be associated with an increased risk of many types of cancers. This study investigates the association between different types…
Abstract Number: 1556 • ACR Convergence 2024
Efficacy and Safety of Anifrolumab Across Organ Domains of Systemic Lupus Erythematosus. A Systematic Review and Meta-Analysis
Mohammad Taha¹, Yomna W Mahmoud¹, Mohammad Ramadan¹, sarah nasir¹, Mariam salah¹, Yassin shenawy², doaa gadelrab¹ and Muhammad abuawwad¹, and ARC team, ¹Cairo university, Cairo, Egypt, ²cairo, cairo, Egypt

Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease affecting multiple organ systems. Anifrolumab is a monoclonal antibody that antagonizes type I interferon receptors,…
Abstract Number: 1852 • ACR Convergence 2024
Uncovering a MAIT-Treg Axis in Skin UV Response: Implications for Photosensitive Reactions in Cutaneous Lupus Erythematosus
Grace Crossland¹, Lindsay Mendyka², Kaitlyn Dowling³, Michael Constantinides⁴ and Sladjana Skopelja-Gardner¹, ¹Dartmouth Geisel School of Medicine, Lebanon, NH, ²Dartmouth Hitchcock Memorial Hospital, Lyme, NH, ³Dartmouth College, Lebanon, NH, ⁴Scripps Research Institute, San Diego, CA
Background/Purpose: Approximately 80% of cutaneous lupus erythematosus (CLE) patients experience sensitivity to ultraviolet (UV) sunlight rays, which leads to disfiguring skin lesions or systemic disease…
Abstract Number: 0297 • ACR Convergence 2024
Characteristics of Adult-Onset Still’s Disease Skin Eruption in Individuals of Sub-Saharan Ancestry
Benoit Suzon¹, Eleonore de Fritsch¹, Arthur Felix¹, Fabienne Louis-sidney², Emmanuelle Amazan¹, Florence Moinet³, Aurore Abel¹, Illitch Coco-Viloin¹, Moustapha Dramé¹, Christophe Deligny⁴ and Pernelle Thomas¹, ¹University Hospital of Martinique, Fort-de-France, Martinique, ²University Hospital Martinique, Fort De France, Martinique, ³University Hospital of Martinique, Fort de France, France, ⁴University Hospital of Martinique - National reference center for autoimmune disease, Internal Medicine, Fort-de-France, Martinique
Background/Purpose: There is no data about adult-onset Still's disease (AOSD) skin eruption in individuals of sub-Saharan ancestry, from basic description to potential clinical implications.Methods: We conducted…
Abstract Number: 1558 • ACR Convergence 2024
Mapping in Healthy Subjects Different Body Areas for Dermal Thickness and Skin Hardness by High Frequency Sonography and Durometry
Maurizio Cutolo¹, Elvis Hysa², Nathalie Berghen³, Tessa Dufour⁴, Andrea Cere⁵, Kaat Wyckstandt³, Emanuele Gotelli¹ and vanessa smith⁶, ¹Laboratory of Experimental Rheumatology and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, IRCCS Ospedale Policlinico San Martino, Genoa, Italy, Genova, Italy, ²Laboratory of Experimental Rheumatology and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, Genoa, Italy, Genoa, Italy, ³University of Ghent, Ghent, Italy, ⁴University Hospital Ghent, Gent, Belgium, ⁵University of Ghent, Ghent, Belgium, ⁶Ghent University Hospital, Gent, Belgium
Background/Purpose: Skin involvement is a prominent feature of systemic sclerosis (SSc). The reliability of non-invasive tools such as high frequency skin ultrasound (HFSU) and durometry,…
Abstract Number: 2056 • ACR Convergence 2024
Deucravacitinib Treatment Did Not Impact Immune Response to SARS-CoV-2 Vaccines and Infection in Patients with Plaque Psoriasis: Results from the Phase 3 POETYK Long-Term Extension Trial
Kevin Winthrop¹, Joseph Merola², Akimichi Morita³, Diamant Thaçi⁴, Jianzhong Zhang⁵, Aditi Basu Ba⁶, Ian M. Catlett⁷, John Schwarz⁶ and Yi Luo⁶, ¹School of Medicine, Oregon Health and Science University, Portland, OR, ²UT Southwestern Medical Center, Newton, MA, ³Department of Geriatric and Environmental Dermatology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan, ⁴Institute and Comprehensive Center for Inflammation Medicine, University of Lübeck, Lübeck, Schleswig-Holstein, Germany, ⁵Department of Dermatology, Peking University People’s Hospital, Beijing, China, ⁶Bristol Myers Squibb, Princeton, ⁷Bristol Myers Squibb, Princeton, NJ
Background/Purpose: Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, is approved in the US, EU, and other countries for treatment of adults with moderate…
Abstract Number: 0303 • ACR Convergence 2024
Phase 2b, Long-term Extension, Dose-ranging Study of Oral JNJ-77242113 for the Treatment of Moderate-to-Severe Plaque Psoriasis: FRONTIER-2
Laura K. Ferris¹, Jerry Bagel², Yu-Huei Huang³, Andrew E. Pink⁴, Stephen K. Tyring⁵, Georgios Kokolakis⁶, Amy M. DeLozier⁷, Daniel Kakaley⁸, Shu Li⁹, Yaung-Kaung Shen¹⁰, Takayuki Ota⁷ and Robert Bissonnette¹¹, ¹University of Pittsburgh, Pittsburgh, PA, ²Psoriasis Treatment Center of Central NJ, East Windsor, NJ, ³Chang Gung Memorial Hospital and Chang Gung University, Linkou, Taoyuan City, Taiwan (Republic of China), ⁴NHS Foundation Trust Great Maze Pond, London, United Kingdom, ⁵Center for Clinical Studies, Webster, TX, ⁶Psoriasis Research and Treatment Center, Department of Dermatology, Venereology and Allergology, Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany, ⁷Janssen Research & Development, LLC, San Diego, CA, ⁸Janssen Scientific Affairs, LLC, Horsham, PA, ⁹Janssen Research & Development, LLC, Spring House, PA/San Diego, CA, ¹⁰Janssen Research & Development, LLC, Spring House, PA, ¹¹Innovaderm Research, Montreal, QC, Canada
Background/Purpose: JNJ-77242113, a targeted oral peptide, inhibits IL-23 signaling by binding the IL-23 receptor. At all doses, JNJ-77242113 showed superior efficacy at Week 16 versus…
Abstract Number: 1586 • ACR Convergence 2024
The Relationship Between the Presence, Quantity and Distribution of Cutaneous Telangiectasia and Other Vascular Manifestations of Systemic Sclerosis
Matthew Wells¹, Robyn Domsic², Ami Shah³, Laura Hummers⁴, Aishwarya Anilkumar¹, Tracy Frech⁵, Ariane Herrick⁶, Christopher Denton⁷, Dinesh Khanna⁸ and John Pauling¹, ¹North Bristol NHS Trust, Bristol, United Kingdom, ²Division of Rheumatology and Clinical Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA, ³Division of Rheumatology, Johns Hopkins University, Ellicott City, MD, ⁴Johns Hopkins University, Division of Rheumatology, Baltimore, MD, Ellicott City, MD, ⁵Vanderbilt University Medical Center, Nashville, TN, ⁶University of Manchester, UK, Aberdeen, United Kingdom, ⁷University College London, Northwood, United Kingdom, ⁸University of Michigan, Ann Arbor, MI
Background/Purpose: Telangiectasia are permanently dilated dermal postcapillary venules and are the 2nd most common manifestation (~80%) of systemic sclerosis (SSc) after Raynaud’s phenomenon (RP). The…
Abstract Number: 2153 • ACR Convergence 2024
Construct Validity of the IDEOM Musculoskeletal Questionnaire (IDEOM MSK-Q) Using Data from the Cohort for Psoriasis and Psoriatic Arthritis Registry (COPPAR)
Lourdes Perez Chada¹, Ruogu Li², vivi feathers², Kumiko Schnock², Helen Early², Grace Carter², Neda Shahriari², Arianna Zhang², Jing Cui³, Michael Weinblatt⁴, Nancy Shadick², Alice Gottlieb⁵ and Joseph Merola⁶, ¹Harvard Medical School, Wayland, MA, ²Brigham and Women's Hospital, Boston, MA, ³Brigham Women's Hospital, Boston, MA, ⁴Brigham and Women's Hospital/ Harvard Medical School, Waban, MA, ⁵Icahn School of Medicine at Mount Sinai, Department of Dermatology, Seattle, WA, ⁶UT Southwestern Medical Center, Newton, MA
Background/Purpose: Patients with psoriasis often present with musculoskeletal (MSK) symptoms, yet validated instruments to measure MSK symptoms in this population are limited. The IDEOM MSK-Q…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].